文献速递青光眼

钠-葡萄糖协同转运蛋白2抑制剂用于2型糖尿病患者青光眼一级预防:目标试验模拟

Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Glaucoma in Patients With Type 2 Diabetes: A Target Trial Emulation.
PubMed 文献 · Am J Ophthalmol · 2024-11-06

该目标试验模拟研究基于美国多个医疗机构2013至2023年的观察性数据,纳入新起始SGLT2i、DPP4i或GLP1RA治疗的2型糖尿病成人,经倾向评分匹配后比较青光眼发生风险。结果示SGLT2i组较DPP4i组青光眼风险更低(HR 0.815,95%CI 0.794, 0.837),开角型与原发性闭角型青光眼风险均降低,与GLP1RA比较亦显示保护效应(HR 0.932,95%CI 0.906, 0.959)。

要点

  • SGLT2i组较DPP4i组青光眼风险更低(HR 0.815,95%CI 0.794, 0.837)。
  • 开角型青光眼HR 0.755(95%CI 0.729, 0.781),原发性闭角型青光眼HR 0.702(95%CI 0.636, 0.781)。
  • 与GLP1RA比较,SGLT2i对青光眼的保护效应得到验证(HR 0.932,95%CI 0.906, 0.959)。

核心结论

  • 使用SGLT2i(包括卡格列净、恩格列净、达格列净和埃格列净)的患者较使用DPP4i者新发青光眼风险显著更低。
  • SGLT2i对开角型青光眼和闭角型青光眼均显示出保护效应。

研究设计与样本

  • 采用目标试验模拟,使用来自美国多个医疗机构的观察性数据。
  • 基于人群的队列研究纳入2013至2023年间新起始SGLT2i、DPP4i或GLP1RA治疗的2型糖尿病成人。
  • 采用倾向评分匹配控制社会人口学特征、合并症及合并用药。
  • 暴露为2型糖尿病接受SGLT2i治疗,结局为起始降糖治疗后新发青光眼及其亚型。
  • 进行亚组分析评估单个SGLT2i对青光眼发生的影响。

主要发现

  • 倾向评分匹配后,SGLT2i组和DPP4i组各纳入722,446例患者。
  • SGLT2i组较DPP4i组青光眼风险更低(HR 0.815,95%CI 0.794, 0.837)。
  • 开角型青光眼HR 0.755(95%CI 0.729, 0.781),原发性闭角型青光眼HR 0.702(95%CI 0.636, 0.781)。
  • 在所有SGLT2i中,埃格列净与青光眼风险最低相关(HR 0.668,95%CI 0.512, 0.871),其次为恩格列净(HR 0.727,95%CI 0.696, 0.759)、达格列净(HR 0.814,95%CI 0.774, 0.855)和卡格列净(HR 0.893,95%CI 0.862, 0.926)。
  • 与GLP1RA比较,SGLT2i对青光眼的保护效应得到验证(HR 0.932,95%CI 0.906, 0.959)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pleiotropic cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors (SGLT2i) due to vascular remodeling effects have been demonstrated in patients with type 2 diabetes mellitus. It is unclear whether a similar benefit may be seen for glaucoma. The purpose of this study was to assess the effect of SGLT2i on the risk of glaucoma in patients with type 2 diabetes. DESIGN: Target trial emulation using observational data from multiple healthcare organizations. METHODS: This population-based cohort study included adults with type 2 diabetes in the United States who newly initiated treatment with SGLT2i, dipeptidyl peptidase 4 inhibitors (DPP4i), or glucagon-like peptide-1 receptor agonists (GLP1RA) between 2013 and 2023. Propensity score matching was conducted to control for sociodemographic characteristics comorbidities, and concomitant use of medications. The exposure considered was treatment with SGLT2i for type 2 diabetes, and the outcomes were new-onset glaucoma and its subtypes after initiation of antidiabetic treatments. Subgroup analyses were performed to evaluate the effect of individual SGLT2i on incident glaucoma. RESULTS: After propensity score matching, 722,446 patients were included in the SGLT2i arm and the DPP4i arm, respectively. Patients on SGLT2i, compared with those on DPP4i, had a lower risk of glaucoma (hazard ratio [HR] 0.815, 95% confidence interval [CI] 0.794, 0.837), including open-angle glaucoma (HR 0.755, 95% CI 0.729, 0.781) and primary angle-closure glaucoma (HR 0.702, 95% CI 0.636, 0.781). Among all SGLT2i, ertugliflozin (HR 0.668, 95% CI 0.512, 0.871) was associated with the lowest risk of glaucoma, followed by empagliflozin (HR 0.727, 95% CI 0.696, 0.759), dapagliflozin (HR 0.814, 95% CI 0.774, 0.855), and canagliflozin (HR 0.893, 95% CI 0.862, 0.926). The protective effect of SGLT2i on glaucoma was validated when compared with GLP1RA (HR 0.932, 95% CI 0.906, 0.959). CONCLUSIONS: Patients on SGLT2i, including canagliflozin, empagliflozin, dapagliflozin, and ertugliflozin, had a significantly lower risk of incident glaucoma compared to those on DPP4i. SGLT2i demonstrated a protective effect for both open-angle glaucoma and angle-closure glaucoma.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Eng K, Zebardast N, Boland MV, et al. Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Glaucoma in Patients With Type 2 Diabetes: A Target Trial Emulation. Am J Ophthalmol. 2024. PMID: 39515454. doi:10.1016/j.ajo.2024.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。